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Background
Breast cancer is a major health concern in Qatar with a
younger age at diagnosis and projections of 60% increase
in new cases. Triple negative breast cancer (TNBC) is
associated with advanced disease at diagnosis and poorer
outcome, and can be subclassified into 6 gene-expression-
based subtypes. These patients don’t benefit from endo-
crine or HER2-targeted therapy and represent 15-20% of
cases mandating the need for novel treatments. Although
immunotherapy has shown promising results in different
cancers, there are only 2 clinical trials to date assessing
adoptive cell immunotherapy in TNBC. Cancer testis anti-
gens (CTA) could be good candidate targets as their
expression is often up-regulated in malignant tissues,
while it is restricted in the testis and absent or very low in
other somatic tissues.
Methods
We mined the TCGA and NCBI GEO repositories for
genomic data on CTA expression in TNBC and selected
a panel of 15 CTAs for further investigation. Gene and
protein expression was investigated in a series of
9 human TNBC cell lines, encompassing all subtypes.
Results
We found the gene expression of TSAG10, MAGEA5,
PLAC1, and DKKL1 to be moderate/highly expressed in
our cell lines and in both datasets, and are confirming
this on protein level. We are establishing a biobank of
DNA and RNA of Qatari breast cancer patients and will
present gene expression data of CTAs in TNBC tumors.
Conclusions
Our preliminary findings suggest that TSAG10, MAGEA5,
PLAC1 and DKKL1 could be good candidate targets for
TNBC immunotherapy, and in particular could benefit
Qatari breast cancer patients.
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